Efficacy and Safety of Percutaneous Microwave Coagulation Therapy for Experimental VX2 Lung Cancer in Rabbits
HU Hai-Yang1, LI Qiang1, HAN Zhi-Gang2, KANG De-Qiang1 1. Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai, 200433, P. R. China 2. Department of Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, P. R. China
BACKGROUND OBJECTIVE: Percutaneous microwave coagulation therapy (PMCT) is an important mini-invasive technique used to treat solid tumors. This study was to evaluate the efficacy and safety of PMCT with a new homemade equipment for experimental VX2 lung carcinoma in rabbits, and optimize technical parameters. METHODS: VX2 lung cancer model was established in 30 New Zealand rabbits by tissue clot suspension injection. The rabbits were divided into 3 groups: the rabbits in control group received sham operation; those in surgical A group and surgical B group were treated with computed tomography (CT)-guided PMCT at 40 W for 120 s or at 80 W for 60 s. General status of the rabbits after operation were observed. The rabbits were scanned with CT weekly to monitor tumor growth. Right after or 1 or 7 days after operation, 1 rabbit in each group was killed randomly for histologic examination. RESULTS: The success rate of tumor cell transplatation was 100%. The tumor formation rate was 86.7%. The mean survival time was significantly longer in surgical A group and surgical B group than in control group [(62.2±4.4) days and (61.7±4.5) days vs. (39.7±5.3) days, P0.01]. The occurrence rates of pneumothorax after PMCT were 33.3% (2/6) in control group, 55.6% (5/9) in surgical A group, and 33.3% (3/9) in surgical B group (P0.10). CONCLUSION: PMCT is a safe, effective and mini-invasive therapeutic option for lung cancer.